ArticleMolecular and cellular pediatrics2026
Sex differences in the long-term tolerability of BNT162b2 in children and adolescents.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSex differences exist not only in the efficacy but also in adverse event rates of many vaccines. Here we compared the sex differences in the tolerability of BNT162b2 in children younger than 18 years in Germany.
methodsA post-hoc analysis of retrospectively collected tolerability data, collected through an authentication-based survey of legal guardians of children vaccinated with BNT162b2 under the age of 18 years (CoVacU18-study). Primary outcome was the frequency of the four most common post-vaccination symptom categories (local, general, musculoskeletal symptoms, fever) reported after the 1st-4th doses. Data were analyzed according to sex in bivariate analyses and regression models adjusting for age, weight, and dosage. Interactions between sex and age group effects on post-vaccination symptoms were assessed. An active-comparator analysis was applied to compare post-vaccination symptoms after BNT162b2 versus non-SARS-CoV-2 vaccines.
resultsThree thousand two hundred twenty-eight participants (median age 5.7 years, male 49.6%). In logistic regression, female sex was associated with higher odds of local symptoms (OR = 1.28 [95% CI: 1.17-1.40], p < 0.05), general symptoms (OR = 1.27 [1.13-1.44], p < 0.05), and musculoskeletal symptoms (OR = 1.27 [1.03-1.56], p < 0.05). Interactions between sex and age groups existed for post-vaccination local symptoms. Following non-BNT162b2 childhood vaccinations, female sex was not associated with odds of any post-vaccination symptoms. No relevant interaction existed between vaccine types (BNT162b2 vs non-BNT162b2) and sex for the association with post-vaccination symptoms.
conclusionSex differences exist in post-vaccination symptoms after BNT162b2 administration in young children and adolescents. These are of importance for the conception of approval studies, for post-vaccination monitoring and for future vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.